2012 China's pharmaceutical product import and export reached 80 billion US dollars

In 2012, the total value of China's imports and exports of pharmaceutical products was US$80.95 billion, an increase of 10.5%, and a record high. Among them, exports of 47,600 million US dollars, an increase of 6.9%; imports of 33.35 billion US dollars, an increase of 15.9%. Foreign trade surplus of 14.25 billion US dollars, a year-on-year decrease of 9.5%.

It is understood that in the three major categories of export commodities, Western medicine and medical device products have respectively exported 27.52 billion U.S. dollars and 17.59 billion U.S. dollars, and their total exports accounted for 94.8%.

Among them, a trend worthy of attention is: China's pharmaceutical companies are accelerating the process of international registration and certification. According to Xu Ming, vice president of the Medical Insurance Association, in 2012, China's pharmaceutical companies submitted 1,259 applications to the US Food and Drug Administration (FDA); they submitted CEP to the EDQM. 173 applications were filed, an increase of 34.1% compared with the same period of 2011, and the total number of valid certificates was 393.

In addition, the formulation exports also usher in development inflection points. According to the statistics of the association, Western medicine has not been the main export product for a long time. However, in 2012, Western medicines exports grew at a high rate, with an increase of 17.9% in export value, showing strong development momentum.

For example, Huahai Pharmaceutical Co., Ltd. formulated a development strategy for overseas expansion in 2007, and it will finally enter the harvest period by 2012. Huahai Pharmaceutical's 2012 performance forecast indicates that the sales of the company's preparations are growing rapidly, and is expected to increase by about 200% over the same period of last year. The latest research report of Changjiang Securities also predicts that the growth rate of the company's formulation export business will still exceed 100% in 2013. The growth rate will remain for 2 to 3 years.

It can be said that accelerating the overseas export strategy is also an important starting point for Zhejiang listed companies of bulk pharmaceuticals. According to related parties of Zhejiang Yongtai Technology Shares, before 2011, the export and domestic sales of the pharmaceutical sector were flat; the proportion of export business had risen to 85% by 2012. The company has invested in a subsidiary in the United States and will be related in the future. After the product has obtained the FDA certification, it will be expected to carry out production and sales in the United States.